News and reporting on pediatric cancer.
Researchers used single-cell sequencing to uncover developing brain cell populations from mice and humans with transcriptome features resembling those in pediatric brain tumors.
By looking at genes and pathways with altered expression in tumor samples, researchers uncovered potential treatment targets beyond those provided by tumor DNA testing.
At the NCI's Childhood Cancer Data Initiative Symposium, speakers emphasized measures such as data harmonization and the need for longitudinal data collection.
Though some experts prefer the comprehensive nature of whole-genome sequencing, others find whole-exome sequencing or targeted exome panels to be more useful.
St. Jude investigators are sharing their WGS cancer data through the St. Jude Cloud, as well as tools and pipelines to help other researchers analyze and use it.
Combined DNA/RNA-seq efforts in various settings could lead to new ways of treating kids with drugs meant for adults or to the development of new therapies.
The actual match rate is significantly higher than the 10 percent rate the researchers anticipated they would see when the study began in 2017.
The year-old Princess Máxima Center, based in Utrecht, has turned to bioinformatics firm The Hyve to address integration and interoperability issues.
At the ACMG meeting, a Children's Hospital of Philadelphia researcher described finding relatively high rates of hereditary cancer variants in tumor sequence data.
The variant especially increases stroke risk among childhood cancer survivors who received an intermediate dose of radiation.
In a cartoon, Vox explores the lack of women among this year's winners of the Nobel Prize.
Science reports a new US defense bill would establish two groups aimed at combating foreign influence on research.
Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.
In Cell this week: analysis of tissue clones, metagenomic studies of ocean water samples, and more.